2022 World Conference on Lung Cancer (ePosters)-EP16.04-012. Retrospective Analysis of Non-Small Cell Lung Cancer with Mucinous Histology Subtype

Pdf Summary

A retrospective analysis was conducted to compare the outcomes and clinical features of patients with mucinous histology subtype of non-small cell lung cancer (NSCLC) to those with non-mucinous subtype. The study included 428 patients treated at a medical institution from October 2019 to March 2021.<br /><br />Of the total population, 14.3% displayed mucinous histology, while 85.7% exhibited typical adenocarcinoma (ADC) histology. The demographic data showed no significant differences between the two groups, except for slightly more stage 3 patients in the mucinous histology group.<br /><br />The primary endpoints of the study were time to disease progression and time to all-cause mortality. The analysis showed that patients with mucinous histology had a statistically significant shorter time to disease progression compared to those with non-mucinous histology. However, there was no significant difference in the 5-year overall survival between the two groups.<br /><br />Next generation data analysis revealed that KRAS mutation was more common in patients with mucinous histology, while EGFR mutation was more common in patients with non-mucinous ADC. PDL-1 expression did not differ significantly between the groups.<br /><br />Univariate analysis identified KRAS mutation as a predictor of shorter time to progression and worse overall survival. On the other hand, EGFR mutation was associated with longer time to progression and better overall survival.<br /><br />The study suggests that differences in outcomes between mucinous and non-mucinous histology may not be as clinically meaningful as previously suggested. The findings support current literature which suggests that KRAS mutation is more common in mucinous histology and is associated with worse prognosis.<br /><br />The study has certain limitations, including a limited number of patients with available data for certain markers. However, the findings highlight the need for novel approaches targeting KRAS mutations to potentially improve outcomes for patients with mucinous histology NSCLC.

Asset Subtitle

Katherine Garcia

Meta Tag

Speaker Katherine Garcia

Topic Tumour Biology and Biomarkers - Tumour Biology & Preclinical Studies

Keywords

retrospective analysis

mucinous histology

non-small cell lung cancer

NSCLC

outcomes

disease progression

KRAS mutation

EGFR mutation

overall survival

prognosis